Last update 08 May 2025

NLRC4 x NLRP3 x RT

Basic Info

Related Targets
NLRC4NLRP3RT

Related

1
Drugs associated with NLRC4 x NLRP3 x RT
Kamuvudine-9
Target
NLRC4 x NLRP3 x RT
Mechanism
NLRC4 inhibitors [+2]
Active Org.
Inflammasome Therapeutics, Inc.Inflammasome Therapeutics, Inc.
 [+1]
Originator Org.
Inflammasome Therapeutics, Inc.Inflammasome Therapeutics, Inc.
Active Indication
Diabetic macular oedema [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with NLRC4 x NLRP3 x RT
NCT06781255
/ RecruitingPhase 1IIT
Evaluation of K9 in Subjects with Diabetic Macular Edema (DME)
NCT06467435
/ RecruitingPhase 1IIT
Evaluation of K9 in Subjects with Thyroid Eye Disease (TED)
100 Clinical Results associated with NLRC4 x NLRP3 x RT
Login to view more data
100 Translational Medicine associated with NLRC4 x NLRP3 x RT
Login to view more data
0 Patents (Medical) associated with NLRC4 x NLRP3 x RT
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free